Pancreatic size and fat content in diabetes: A systematic review and meta-analysis of imaging studies

Tiago Severo Garcia1*, Tatiana Helena Rech2, Cristiane Bauermann Leitão1,3

1 Post-graduate Program in Medical Sciences: Endocrinology, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil, 2 Intensive Care Unit, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil, 3 Endocrine Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil

* tseverogarcia@hotmail.com

Abstract

Objectives

Imaging studies are expected to produce reliable information regarding the size and fat content of the pancreas. However, the available studies have produced inconclusive results. The aim of this study was to perform a systematic review and meta-analysis of imaging studies assessing pancreas size and fat content in patients with type 1 diabetes (T1DM) and type 2 diabetes (T2DM).

Methods

Medline and Embase databases were performed. Studies evaluating pancreatic size (diameter, area or volume) and/or fat content by ultrasound, computed tomography, or magnetic resonance imaging in patients with T1DM and/or T2DM as compared to healthy controls were selected. Seventeen studies including 3,403 subjects (284 T1DM patients, 1,139 T2DM patients, and 1,980 control subjects) were selected for meta-analyses. Pancreas diameter, area, volume, density, and fat percentage were evaluated.

Results

Pancreatic volume was reduced in T1DM and T2DM vs. controls (T1DM vs. controls: -38.72 cm³, 95%CI: -52.25 to -25.19, I² = 70.2%, p for heterogeneity = 0.018; and T2DM vs. controls: -12.18 cm³, 95%CI: -19.1 to -5.25, I² = 79.3%, p for heterogeneity = 0.001). Fat content was higher in T2DM vs. controls (+2.73%, 95%CI 0.55 to 4.91, I² = 82.0%, p for heterogeneity <0.001).

Conclusions

Individuals with T1DM and T2DM have reduced pancreas size in comparison with control subjects. Patients with T2DM have increased pancreatic fat content.
Introduction

The pancreas plays a key role in diabetes mellitus, a progressive disease characterized by chronic hyperglycemia [1] in the context of insulin resistance [2] and/or beta cell dysfunction and death [3]. Beta cell loss secondary to apoptosis leads to a reduction in beta cell mass [4, 5]. Although islets of Langerhans represent only 1% of the total pancreas, autopsy studies have demonstrated reduced pancreas size in both type 1 [6] and type 2 diabetic subjects [7].

Insulin deficiency and the lack of a trophic effect of insulin on acinar cells [6] as well as the chronic inflammation associated with insulitis [8, 9] may explain the reduction in pancreas size in type 1 diabetes (T1DM), whereas atherosclerosis might play a role in type 2 diabetes (T2DM) [10, 11]. In both type 1 and type 2 diabetes, pancreatic size reduction may also be associated to exocrine pancreatopathy [12, 13]. However, the reduction in pancreatic size may also be the cause, and not a consequence of diabetes [14, 15].

Imaging studies are expected to produce reliable information regarding pancreas size. However, while some studies using ultrasound (US), computed tomography (CT), and magnetic resonance imaging (MRI) to assess pancreas size in diabetes have shown reduced pancreatic size in individuals with diabetes as compared to controls [16–18], no differences were observed in others [19, 20]. Such inconclusiveness may be related to the small sample size of most studies evaluating this issue.

Interestingly, CT and MRI are widely used to measure liver steatosis [21, 22], which is closely related to obesity and diabetes [22]. More recently, imaging protocols have produced accurate non-invasive measurements of pancreatic fat content in humans [23, 24]. Excess ectopic fat storage has been linked to insulin resistance [22], and pancreatic fat content has been negatively associated with insulin secretion [25].

The aim of the present study was to systematically review the literature and synthesize data regarding pancreatic size and fat content in diabetes using meta-analysis.

Methods

Data sources and searches

To identify observational studies evaluating pancreatic size or fat content by imaging in diabetes, the literature (Medline and Embase) was searched for studies using the three major imaging methods (US, CT, and MRI) for pancreas evaluation from inception until May 2017. No language or date restrictions were applied. Medical subject heading (MeSH) terms and key words included in the search were as follows: pancreas, diabetes, imaging, radiology, ultrasound, tomography, and magnetic resonance. Detailed Medline and Embase search strategies are shown as Fig 1. Also, the references of selected articles were manually searched. Titles and abstracts of all retrieved articles were independently reviewed by two physicians, T.S.G (radiologist) and T.H.R. Disagreements were resolved by consensus. The full text of selected articles was examined. The study is registered at PROSPERO under the number 2016: CRD42016039853.

Study selection

We included prospective and retrospective observational studies evaluating pancreatic size and/or fat content by US, CT, or MRI in T1DM and/or T2DM patients as compared to non-diabetic subjects. Exclusion criteria were as follows: case report design, inclusion of pediatric patients (<12 years), absence of control group, and no clear description of imaging and post-processing technique. If duplicate studies were detected, the most complete report with the longest follow-up was included.
Data extraction

One reviewer (T.S.G) conducted data extraction and a second investigator checked data extraction for accuracy (T.H.R). Data were extracted on year of publication, number of T1DM, T2DM, and non-diabetic subjects, and imaging method used for pancreatic assessment. In addition, the following data were extracted on pancreatic parameters (mean and standard deviation) in the three groups of interest (T1DM, T2DM, and non-diabetic subjects): pancreatic diameter in cm, area in cm$^2$, volume in cm$^3$, density in Hounsfield units (HU), and percentage of pancreatic fat.

Quality assessment

Quality assessment of studies included in meta-analyses was performed using the Newcastle-Ottawa scale [26], a scoring system that takes into account selection of groups, comparability between groups, and ascertainment of the exposure (in the case of studies included in this meta-analysis, it refers to the imaging method and to the technique by which parameters were measured).

Data synthesis and analysis

Absolute changes in size (diameter, area, or volume), density, and fat percentage in patients with diabetes and control groups are presented as means ± standard deviation (SD). Cochran's Q test was used to evaluate heterogeneity between studies. A p value <0.1 was considered statistically significant. The $I^2$ test was also conducted to evaluate the magnitude of the heterogeneity.
between studies. Heterogeneity was defined as $I^2 > 50\%$. A random effects model was used for all analyses.

The contribution of individual studies to the overall heterogeneity was explored using meta-regression, subgroup analyses, and sensitivity analyses by removing each study at a time and re-running the meta-analyses. In some cases, these procedures were not feasible due to an insufficient number of studies/patients.

Funnel plot asymmetry was evaluated by Begg and Egger tests. The impact of small-study bias was considered as significant if $p$ value < 0.1 [27]. Analyses were conducted using Stata software version 11.0 (Stata Inc, College Station, Texas).

**Results**

A total of 5,634 potentially relevant studies were initially identified, 1,532 in Medline and 4,102 in Embase. Hand search of reference lists resulted in the inclusion of an additional eight articles (5,642 articles). After removal of 1,047 duplicates, 4,595 citations were screened based on titles and abstracts. Twenty-nine were selected for full-text review, and finally 23 articles and one poster fulfilled the inclusion criteria.

Of the 24 studies selected, seven were not included in the meta-analysis: in six, data were not extractable [12, 24, 28–31], and in one study measuring pancreatic fat divided by splenic fat the parameters of interest could not be combined [23]. The remaining 17 studies were included in meta-analyses: two evaluating diameter [19, 32], two evaluating area [16, 33] eight evaluating volume [17, 18, 20, 34–38], two evaluating density [17, 39], and six evaluating fat content [17, 18, 40–43]. Studies assessing multiple parameters were included in more than one meta-analysis. The flowchart of study selection is depicted in Fig 2.

Characteristics of the studies included in the systematic review and meta-analyses are presented in Table 1. The studies were published between 1985 and 2015 and included 3,403 participants: 284 T1DM patients (minimum-maximum: 12 to 60 patients), 1,139 T2DM patients (11 to 198 patients), and 1,980 control subjects (9 to 660 patients). Overall mean age was 59.4 years (minimum-maximum: 13 to 100 years) (33.9 in T1DM, 58.1 in T2DM, and 63.0 years in controls), and overall mean BMI was 26.84 kg/m$^2$ (22.72 kg/m$^2$ in T1DM, 27.05 kg/m$^2$ in T2DM, and 27.21 kg/m$^2$ in controls). Mean duration of disease was 8.9 years in T1DM and 6.5 years in T2DM. CT scanners used for evaluation of pancreatic volume ranged from one to 64-detector-rows. MRI evaluating pancreatic volume and/or pancreatic fat percentage was performed in 1.5 T or 3.0 T scanners. In both CT and MRI scans, the contour of the pancreas in each slice was annotated, automatically generating the area of each slice. Pancreatic volume was then calculated by multiplying the area of pancreatic tissue on each section by the interval between slices. MRI methods for estimation of pancreatic fat content included spectroscopy or chemical shift sequences for separation of water and fat. CT quantification of pancreatic fat was performed by means of a histogram.

**Pancreatic size**

**Volume.** Eight studies were included in meta-analyses focusing on volume [17, 18, 20, 34–38]. In four studies [20, 34, 36, 37] with T1DM patients, pancreas volume was reduced as compared to control subjects (−38.72 cm$^3$; 95% CI −52.25 to −25.19). However, between-study heterogeneity was high ($I^2 = 70.2\%$, $p$ for heterogeneity = 0.018) (Fig 3A).

Heterogeneity was explored by sensitivity analysis and each study was excluded at a time. Heterogeneity was reduced to 47.8% ($p$ for heterogeneity = 0.147) after omission of the study by Goda et al [20], while no change was observed when other studies were excluded. This may have resulted from patient selection bias, as the mean age of T1DM patients in this study was
48.7 years, while the mean duration of diabetes was 9.4 years—suggesting that T2DM patients may have been misdiagnosed with T1DM. Interestingly, this was the only study using CT for volume assessment, and thus sensitivity and subgroup analysis of pancreatic volume based on image technique were coincident; in this study, pancreatic volume in T1DM patients was 26.3 cm$^3$. 

Fig 2. Flowchart of study selection.
https://doi.org/10.1371/journal.pone.0180911.g002
smaller than that of controls (95%CI, -37.16 to -15.44). Moreover, the present meta-analysis of MRI studies shows a mean reduction of -44.08 cm³ (95%CI -57.16 to -30.99) in pancreatic

Table 1. Summary of studies evaluating pancreas size and fat content by imaging methods in diabetes.

| Authors, year | No. of subjects | Results |
|---------------|-----------------|---------|
| Fonseca et al, 1985 [28] | 32 Type 1 diabetes | 45.2±19.5 |
| Silva et al, 1993* [19] | 36 Type 2 diabetes | 49.39±5.84 |
| Alzaid et al, 1993* [16] | 43 Type 1 diabetes | 10.2±3.0 |
| Rajput et al, 2001* [33] | 35 Type 2 diabetes | 0.94±0.21 |
| Basiratnia et al, 2007* [32] | 60 Controls | 1.2±0.3 |
| Fonseca et al, 1985 [28] | 32 Type 1 diabetes | 1.9±0.3⁴ |
| Silva et al, 1993* [19] | 36 Type 2 diabetes | 9.0±0.2⁵ |
| Alzaid et al, 1993* [16] | 43 Type 1 diabetes | 2.7±0.4 |
| Rajput et al, 2001* [33] | 35 Type 2 diabetes | 1.2±0.3 |
| Basiratnia et al, 2007* [32] | 60 Controls | 2.4±0.4 |
| Silva et al, 1993* [19] | 36 Type 2 diabetes | 0.9±0.2⁵ |
| Alzaid et al, 1993* [16] | 43 Type 1 diabetes | 2.7±0.4 |
| Rajput et al, 2001* [33] | 35 Type 2 diabetes | 1.2±0.3 |
| Basiratnia et al, 2007* [32] | 60 Controls | 2.4±0.4 |
| Gilbeau et al, 1992* [39] | 37 Type 1 diabetes | 37.62±15.14 |
| Silva et al, 1993* [19] | 36 Type 2 diabetes | 40.00±15.10 |
| Rajput et al, 2001* [33] | 0 Type 1 diabetes | 1.9±0.3 |
| Basiratnia et al, 2007* [32] | 60 Type 2 diabetes | 0.9±0.2⁵ |
| Fonseca et al, 1985 [28] | 32 Type 1 diabetes | 10.2±3.0 |
| Silva et al, 1993* [19] | 36 Type 2 diabetes | 0.9±0.2⁵ |
| Alzaid et al, 1993* [16] | 43 Type 1 diabetes | 2.7±0.4 |
| Rajput et al, 2001* [33] | 35 Type 2 diabetes | 1.2±0.3 |
| Basiratnia et al, 2007* [32] | 60 Controls | 2.4±0.4 |
| Goda et al, 2001* [20] | 29 Type 1 diabetes | 49.39±5.84 |
| Phillipe et al, 2001 [12] | 28 Type 2 diabetes | 6.7±6.1 |
| Saisho et al, 2007* [35] | 165 Type 1 diabetes | 53.8±13.4 |
| Yokota et al, 2012 [29] | 62 Type 2 diabetes | 54.60±5.80 |
| Lim et al, 2014* [17] | 0 Type 1 diabetes | 9.0±0.2⁵ |
| Williams et al, 2007* [34] | 12 Type 2 diabetes | 6.9±1.6 |
| Sequeiros et al, 2010* [36] | 0 Type 1 diabetes | 6.9±1.6 |
| Lim et al, 2011* [40] | 11 Type 1 diabetes | 6.9±1.6 |
| Williams et al, 2012 [37] | 0 Type 2 diabetes | 6.9±1.6 |
| Burute et al, 2014* [38] | 32 Type 1 diabetes | 72.7±20.7 |
| Ma et al, 2014* [41] | 24 Type 2 diabetes | 89.6±22.7 |
| Percival et al, 2014* [43] | 71 Type 1 diabetes | 18.2±12.5 |
| Macauley et al, 2015* [18] | 41 Type 2 diabetes | 4.9±12.5 |
| Kuhn et al, 2015* [42] | 0 Type 1 diabetes | 4.9±12.5 |
| Begovatz et al, 2015 [31] | 14 Type 2 diabetes | 4.9±12.5 |

US: ultrasound; CT: computed tomography; MRI: magnetic resonance image; fat% (s): pancreatic fat percentage obtained by MRI spectroscopy; fat% (c): pancreatic fat% obtained by MRI chemical shift imaging.

Results are shown as mean±SD.

https://doi.org/10.1371/journal.pone.0180911.t001

*: studies included in meta-analyses.
Diameter is shown in cm; area in cm²; volume in cm³; density in HU; fat in %.
Fig 3. Meta-analyses of studies evaluating pancreas by imaging in diabetes. (A) Forest plot comparing pancreas volume (cm$^3$) in type 1 diabetic patients with a control group. (B) Forest plot comparing pancreas...
volume in T1DM patients vs. controls. Subgroup analyses were performed based on the quality of studies (including only studies with a score of 6–8 in the Newcastle-Ottawa scale or studies where cases and controls were matched by BMI. However, heterogeneity was not affected by these variables (data not shown).

Despite the small number of studies, we performed meta-regression with age, BMI, and duration of diabetes as covariates. Although not statistically significant, a reduction in heterogeneity from 70.2% to 52.7% (p = 0.355) was observed in the model considering duration of diabetes. Interestingly, the T1DM patients with longer diabetes duration had the lowest pancreatic volume (Fig 4).

Similar results were observed for pancreatic volume in five studies[17, 18, 20, 35, 38] with T2DM patients, whose pancreas was smaller than that of controls (-12.18 cm$^3$; 95%CI: -19.1 to -5.25, $I^2 = 79.3\%$, p for heterogeneity = 0.001) (Fig 3B). Sensitivity analysis excluding individual studies did not decrease heterogeneity (data not shown). However, subgroup analysis considering imaging methods showed lower heterogeneity for MRI studies ($I^2 = 47.6\%$, p for heterogeneity = 0.167) in comparison with CT studies ($I^2 = 70\%$, p for heterogeneity = 0.035). It should be noted that pancreas volume was smaller in T2DM patients vs. controls regardless of imaging technique (MRI: -21.65 cm$^3$ [95%CI -31.62 to -11.68] and CT: -7.5 cm$^3$ [95%CI -13.65 to -1.36]). As for T1DM, subgroup analyses considering only studies rated 6–8 in the Newcastle-Ottawa scale or studies with BMI-matched T2DM patients did not change heterogeneity (data not shown). No variable included in meta-regression was associated with heterogeneity.

Only one study [12] compared pancreas volume in T1DM and T2DM patients, precluding meta-analysis. In this CT study, no significant differences in volume were detected between T1DM and T2DM patients.
Diameter. Two studies\[19, 32\] using US detected a smaller pancreatic diameter (measured at the head and body) in T1DM patients as compared to controls (head diameter: \(-0.6\) cm [95%CI: \(-0.8\) to \(-0.41\)], \(I^2 = 77.8\%\), p for heterogeneity = 0.034; and body diameter: \(-0.38\) cm [95%CI: \(-0.73\) to \(-0.03\)], \(I^2 = 97.2\%\), p for heterogeneity < 0.001). However, no differences were found when T2DM patients and controls were compared (head diameter: \(-0.02\) cm [95%CI: \(-0.63\) to \(0.6\)], \(I^2 = 97\%\), p for heterogeneity < 0.001; and body diameter: \(-0.16\) cm [95%CI: \(-0.66\) to \(0.34\)], \(I^2 = 97.9\%\), p for heterogeneity < 0.001).

A meta-analysis comparing pancreas diameter in T1DM and T2DM revealed that both head diameter (\(-0.58\) cm [95%CI: \(-1\) to \(-0.16\)], \(I^2 = 94.5\%\), p for heterogeneity < 0.001) and body diameter (\(-0.22\) cm [95%CI: \(-0.36\) to \(-0.07\)], \(I^2 = 79.3\%\), p for heterogeneity = 0.028) were smaller in T1DM patients.

Area. Two US studies \[16, 33\] analyzed T1DM patients regarding pancreatic area, which was significantly smaller as compared to that of controls (\(-5.44\) cm\(^2\) [95%CI: \(-6.8\) to \(-4.08\)], \(I^2 = 1.9\%\), p for heterogeneity = 0.313). Another study \[28\], which was not meta-analyzed due to lack of extractable data, corroborated these findings, showing reduced pancreas area in T2DM, and especially T1DM patients.

Pancreatic fat content

Six studies\[17, 18, 40–43\] including only T2DM patients evaluated pancreatic fat content in terms of fat percentage, which was higher in T2DM patients as compared to control subjects (\(+2.73\%\) [95%CI: 0.55 to 4.91], \(I^2 = 82.0\%\), P for heterogeneity < 0.001) (Fig 3C). Heterogeneity was not explained by either sensitivity analysis/meta-regression (data not shown) or subgroup analysis based on imaging methods; only one study \[17\] measured pancreatic fat content by CT. Meta-analysis of the additional five studies \[18, 40–43\], all of which used MRI, did not change heterogeneity (\(I^2 = 75.7\%\), p for heterogeneity = 0.002). Similarly, heterogeneity was unchanged in subgroup analyses of studies with Newcastle-Ottawa scores of 6–8 or of studies with BMI-matched groups (data not shown).

Pancreatic density is an indirect form of evaluating fat content, as fat-enriched tissues have lower densities. Pancreatic density assessed by CT in two studies \[17, 39\] was lower in T2DM patients vs. control subjects (\(-4.98\)HU [95%CI: \(-6.76\) to \(-3.21\)], \(I^2 = 0\%\), p for heterogeneity = 0.395).

Interestingly, Yokota et al demonstrated a decrease in pancreatic density with increasingly impaired glucose homeostasis\[29\]. Healthy individuals had higher pancreatic densities, which decreased progressively from impaired glucose tolerance to diabetes \[29\]. However, Begovatz et al did not find differences in pancreatic fat content between subjects with normal glucose, impaired fasting glucose, or T2DM patients when pancreatic fat was evaluated by MRI \[31\].

Quality of studies and small-study bias

The studies included in meta-analyses were assessed for quality using the Newcastle-Ottawa scale (Table 2). Overall, studies had low/moderate quality; most had a score of 6 or 7 points from a maximum of 9.

The funnel plot asymmetry test revealed no major small-study bias regarding volume or fat content in T2DM patients (p = 0.458 and 0.484 respectively). However, a possible small-study bias was detected for volume in T1DM patients (p = 0.041).

Discussion

In this systematic review with meta-analysis of imaging studies, a reduction in pancreatic size was observed in both T1DM and T2DM patients. In addition, an increase in pancreatic fat content was seen in T2DM subjects.
Pancreatic size was evaluated in terms of diameter, area, and volume. In T1DM patients, the results show decreased pancreatic size in comparison to non-diabetic controls for all three parameters. In turn, volume, but not diameter, was reduced in T2DM patients; area was not meta-analyzed because only one study focusing on this aspect included T2DM subjects. Interestingly, a comparison between T1DM and T2DM revealed smaller pancreatic diameter in T1DM individuals. A single study assessing pancreatic area showed smaller dimensions in T1DM individuals vs. T2DM individuals, and the only study assessing volume observed no differences between T1DM and T2DM patients. Volume, which provides three-dimensional data, is the best parameter to assess organ size. The present findings show smaller pancreatic volume in both T1DM and T2DM patients in relation to controls, but data are insufficient to establish a firm conclusion regarding the comparison between these two types of diabetes. However, our meta-analyses focusing on volume suggest that T1DM subjects may in fact have smaller pancreatic volume in relation to T2DM individuals: a difference of –38.72 cm$^3$ (95%CI –52.25 to –25.19) was observed for T1DM vs. controls, and a difference of –12.18 cm$^3$ (95%CI –19.1 to –5.25) was observed for T2DM vs. controls. Although a formal statistical test was not performed, it is fair to assume that pancreatic volume was smaller in T1DM than T2DM patients, since the 95% CIs did not overlap.

An intriguing finding of this systematic review is the low heterogeneity of MRI studies, as opposed to the high heterogeneity of CT studies. This might be due to the fact that the MRI studies cover a shorter time interval and more recent years (2007–2015) as opposed to the CT studies (1992–2014). Moreover, the magnitude of volume reduction detected by each imaging method was remarkably different (T1DM: –44.08 cm$^3$ for MRI vs. –26.3 cm$^3$ for CT; T2DM: –21.65 cm$^3$ for MRI vs. –7.5 cm$^3$ for CT), with MRI showing consistently higher differences in volumes between patients with diabetes and controls than the results obtained by CT. These differences were unexpected, since the tool used to measure pancreatic volume is similar in

---

**Table 2. Newcastle-Ottawa quality assessment of studies included in meta-analyses.**

| Authors, year | Selection | Comparability | Outcome | Score |
|---------------|-----------|---------------|---------|-------|
| Gilbeau et al, 1992 [39] | * | ** (age, diabetes duration) | * | 6 |
| Silva et al, 1993 [19] | * | | * | 4 |
| Alzaid et al, 1993 [16] | * | | * | 6 |
| Rajput et al, 2001 [33] | * | ** (age, sex, BMI) | * | 7 |
| Goda et al, 2001 [20] | * | ** (age, sex) | * | 7 |
| Basiratnia et al, 2007 [32] | * | * | ** (age, sex) | * | 8 |
| Saisho et al, 2007 [35] | * | * | ** (age, BMI) | * | 8 |
| Williams et al, 2007 [34] | * | | * | 5 |
| Sequeiros et al, 2010 [36] | * | ** (age, sex) | * | 7 |
| Lim et al, 2011 [40] | * | ** (age, sex, weight) | * | 7 |
| Williams et al, 2012 [37] | * | * | ** (age, weight) | * | 8 |
| Lim et al, 2014 [17] | * | * | ** (age, BMI) | * | 6 |
| Burute et al, 2014 [38] | * | * | ** (age, sex, weight) | * | 8 |
| Ma et al, 2014 [41] | * | * | (age) | * | 6 |
| Percival et al, 2014 [43] | * | | * | 4 |
| Kühn et al, 2015 [42] | * | ** (age, sex, BMI) | * | 7 |
| Macauley et al, 2015 [18] | * | ** (age, sex, weight) | * | 6 |

The number of stars indicates the quality of each item evaluated: minimum 0, maximum 1 star for selection and outcome; and minimum 0, maximum 2 stars for comparability. The maximum possible overall score is 9.

https://doi.org/10.1371/journal.pone.0180911.t002
both imaging methods and no plausible technical reason can justify lower volumes measured by MRI. Furthermore, a recent study evaluating T1DM patients with MRI or CT did not report differences in pancreas size measured by the two methods [44].

There is a large inter-individual variation in pancreas morphology and volume related to body size and age in healthy populations [45, 46]. This may be a relevant source of confusion in studies with T1DM and T2DM individuals–T1DM patients are usually younger, and, as shown in the present study, possibly have a smaller pancreas; conversely, T2DM patients might be older than controls, and pancreas size may decrease with age [35]. However, most studies in the present review included BMI-and age-matched controls, and neither subgroup analysis nor meta-regression considering these possible confounders showed an impact on heterogeneity. Reduced pancreatic volume and weight are present from early phases of T1DM, as demonstrated by a study comparing the pancreas of T1DM donors and controls [14], even after correction for confounders [15]. Recently, Virostko et al [44] have suggested progressively smaller pancreatic volume with increased duration of T1DM (decline rate of 0.013 cm³/kg per year). This is supported by the findings of our meta-regression showing that T1DM patients with longer disease duration had lower pancreatic volumes. Thus, monitoring variations in pancreatic volume might be useful to predict diabetes in high-risk individuals [14]. Recently, Yun et al have reported that pancreatic volume reduction rate calculated by serial CT volumetry is a significant predictor of new-onset diabetes in patients undergoing pancreaticoduodenectomy[47].

Pancreatic fat content is evaluated by means of density or fat percentage, with percentage being more precise. Some studies suggest an association between increased pancreatic fat and diabetes. Kim et al [23] have shown that two CT indexes—the difference between pancreatic and splenic density and the pancreas to spleen density ratio—are higher in patients with impaired glucose tolerance. In line with this, a study designed to compare pancreatic fat content and beta cell function found increased lipid deposition in the pancreas of diabetic patients as compared to healthy subjects [24]. Furthermore, in T2DM patients, obesity was associated with lower pancreatic density evaluated by CT, indicating higher pancreatic fat content [30]. In reverse order, return of normal insulin secretion and reduction of pancreatic fat content has been demonstrated after eight weeks of a low energy intake diet [40]. Our data indicate that pancreatic fat content is increased in T2DM patients, which may reflect a paracrine effect of insulin. Insulin resistance causes increased insulin secretion by beta cells, and the higher local insulin concentration may induce fat deposition. A similar phenomenon occurs in the liver when pancreatic islets are transplanted into the portal vein [48–50]. Pancreatic islets delivered to the hepatic sinusoids engraft and produce insulin, and focal steatosis is observed in 20% to 60% of islet recipients [48–50]. More interestingly, transplanted islets surrounded by fat have reduced function, probably as a result of lipotoxicity [30, 51]. Conversely, a low-fat diet and leptin overexpression have been shown to reduce fat content around islets, improving islet function in an animal model [51]. Taken together, these findings suggest that pancreatic fat accumulation might be a result of the higher local insulin levels in an insulin-resistant environment, and that pancreatic lipid deposition may further impair islet function.

Our results have some practical implications. First, the finding of a small or fatty pancreas using imaging techniques should prompt a recommendation for proper biochemical investigation of diabetes. Second, as there is some evidence in the literature linking pancreas atrophy in T1DM and T2DM patients with pancreatic exocrine deficiency [12, 13], differential diagnosis of chronic diarrhea in diabetic patients should consider exocrine pancreatopathy, a hypothesis that could be corroborated by diagnostic imaging. Important to say, ultrasonographic evaluation of the pancreas is not as accurate as evaluation by CT or MRI.

The present review has limitations that must be addressed. First, there are few studies assessing each parameter, precluding adequate exploration of heterogeneity and increasing the
risk for small-study bias. Secondly, CT and MRI have different contrast mechanisms to quantify pancreatic fat content, and both lack detail in measurement methodologies. However, MRI is considered to be more reliable. Pancreatic fat measurement by CT is based on a histogram analysis in which an arbitrary threshold of -190 to -30 HU is applied to identify fat containing voxels [17], while MRI uses spectroscopy or chemical shift techniques for this purpose [42]. These differences may explain discrepancies that can possibly be found between CT and MRI regarding pancreatic fat calculation. Thirdly, pediatric patients were excluded, although T1DM has an early age of incidence. As pancreatic volume is constitutionally associated with body size, and children have a relatively small body size, we think it would be better not to compare children with the adult population. Additionally, the overall quality of studies ranged from low to moderate. Furthermore, the studies included in the analysis date from 1985 to 2015, a time interval in which dramatic changes happened in imaging techniques, which might possibly influence the results of volume/area determinations. However, we believe that the findings of increased fat content and decreased pancreas size consistently point in the same direction and should not be dismissed.

In summary, the present data indicate that reduced pancreas size and increased fat content are features of diabetes. Further longitudinal studies are required to elucidate the cause and effect relationship between pancreatic size and diabetes, as well as the possible causes of pancreas shrinkage and fat deposition. A better understanding of the mechanisms of altered pancreas morphology and fat deposition in diabetes may lead to new insights in preventing, predicting, and treating patients with diabetes.

Supporting information
S1 File. PRISMA checklist.

(DOCX)

Acknowledgments
We thank Caroline K. Kramer from the University of Toronto, who kindly provided statistical advice for this manuscript.

Author Contributions
Conceptualization: Tiago Severo Garcia, Tatiana Helena Rech, Cristiane Bauermann Leitão.
Data curation: Tiago Severo Garcia, Tatiana Helena Rech.
Formal analysis: Tiago Severo Garcia, Cristiane Bauermann Leitão.
Methodology: Tiago Severo Garcia, Tatiana Helena Rech, Cristiane Bauermann Leitão.
Supervision: Cristiane Bauermann Leitão.
Writing – original draft: Tiago Severo Garcia, Tatiana Helena Rech, Cristiane Bauermann Leitão.
Writing – review & editing: Tiago Severo Garcia, Tatiana Helena Rech, Cristiane Bauermann Leitão.

References
1. Standards of Medical Care in Diabetes-2016: Summary of Revisions. Diabetes care. 2016; 39 Suppl 1: S4–5. Epub 2015/12/24.
2. Cnop M, Vidal J, Hull RL, Utzschneider KM, Carr DB, Schraw T, et al. Progressive loss of beta-cell function leads to worsening glucose tolerance in first-degree relatives of subjects with type 2 diabetes. Diabetes care. 2007; 30(3):677–82. Epub 2007/03/01. https://doi.org/10.2337/dc06-1834 PMID: 17327430

3. Brozzi F, Nardelli TR, Lopes M, Milliard J, Barthson J, Igoillo-Esteve M, et al. Cytokines induce endoplasmic reticulum stress in human, rat and mouse beta cells via different mechanisms. Diabetologia. 2015; 58(10):2307–16. Epub 2015/06/24. https://doi.org/10.1007/s00125-015-3669-6 PMID: 26099855

4. Butler AE, Janson J, Soeller WC, Butler PC. Increased beta-cell apoptosis prevents adaptive increase in beta-cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action of amyloid. Diabetes. 2003; 52(9):2304–14. Epub 2003/08/28. PMID: 12941770

5. Donath MY, Halban PA. Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications. Diabetologia. 2004; 47(3):581–9. Epub 2004/02/10. https://doi.org/10.1007/s00125-004-1336-4 PMID: 14767595

6. Lohr M, Kloppel G. Residual insulin positivity and pancreatic atrophy in relation to duration of chronic type 1 (insulin-dependent) diabetes mellitus and microangiopathy. Diabetologia. 1987; 30(10):757–62. Epub 1987/10/01. PMID: 3322901

7. Rahier J, Guiot Y, Goebelgs RM, Sempoux C, Henquin JC. Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes, obesity & metabolism. 2008; 10 Suppl 4:32–42. Epub 2008/10/18.

8. Nakanishi K, Kobayashi T, Miyashita H, Okubo M, Sugimoto T, Murase T, et al. Relationships among residual beta cells, exocrine pancreas, and islet cell antibodies in insulin-dependent diabetes mellitus. Metabolism: clinical and experimental. 1993; 42(2):196–203. Epub 1993/02/01.

9. Meier JJ, Bhushan A, Butler AE, Rizza RA, Butler PC. Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration? Diabetologia. 2005; 48(11):2221–8. Epub 2005/10/06. https://doi.org/10.1007/s00125-005-1949-2 PMID: 16205882

10. Stamm BH. Incidence and diagnostic significance of minor pathologic changes in the adult pancreas at autopsy: a systematic study of 112 autopsies in patients without known pancreatic disease. Human pathology. 1984; 15(7):677–83. Epub 1984/07/01. PMID: 6745910

11. Putzke HP, Friedrich G. [Pancreatopath y in diabetes mellitus]. Zentralblatt fur allgemeine Pathologie u pathologische Anatomie. 1986; 131(1):37–41. Epub 1986/01/01. Pankreatopathie bei Diabetes mellitus. PMID: 2422849

12. Philippe MF, Benabadj S, Barbot-Trystram L, Vadrot D, Boizard C, Llarguer E. Pancreatic volume and exocrine and endocrine functions in patients with diabetes. Pancreas. 2011; 40(3):359–63. Epub 2011/02/02. https://doi.org/10.1097/MPA.0b013e3182072032 PMID: 21283038

13. Mohapatra S, Majumder S, Smyrk TC, Zhang L, Matveyenko A, Kudva YC, et al. Diabetes Mellitus Is Associated With an Exocrine Pancreaticopathy: Conclusions From a Review of Literature. Pancreas. 2016; 45(6):1104–10. Epub 2016/02/27. https://doi.org/10.1097/MPA.0000000000000609 PMID: 26918874

14. Campbell-Thompson M, Wasserfall C, Montgomery EL, Atkinson MA, Kaddis JS. Pancreas organ weight in individuals with disease-associated autoantibodies at risk for type 1 diabetes. Jama. 2012; 308(22):2337–9. Epub 2012/12/13. https://doi.org/10.1001/jama.2012.15008 PMID: 23232891

15. Campbell-Thompson ML, Kaddis JS, Wasserfall C, Haller MJ, Pugliese A, Schatz DA, et al. The influence of type 1 diabetes on pancreatic weight. Diabetologia. 2016; 59(1):217–21. Epub 2015/09/12. https://doi.org/10.1007/s00125-015-3752-z PMID: 26358584

16. Alzaid A, Aideyan O, Nawaz S. The size of the pancreas in diabetes mellitus. Diabetic medicine: a journal of the British Diabetic Association. 1993; 10(8):759–63. Epub 1993/09/10.

17. Lim S, Bae JH, Chun EJ, Kim H, Kim SY, Kim KM, et al. Differences in pancreatic volume, fat content, and fat density measured by multidetector-row computed tomography according to the duration of diabetes. Acta diabetologica. 2014; 51(5):739–48. Epub 2014/03/29. https://doi.org/10.1007/s00125-014-0581-3 PMID: 24671510

18. Macauley M, Percival K, Thelwall PE, Hollingsworth KG, Taylor R. Altered volume, morphology and composition of the pancreas in type 2 diabetes. PloS one. 2015; 10(5):e0126825. Epub 2015/05/06. https://doi.org/10.1371/journal.pone.0126825 PMID: 25950180

19. Silva ME, Vezozzo DP, Ursich MJ, Rocha DM, Cerri GG, Wajchenberg BL. Ultrasonographic abnormalities of the pancreas in IDDM and NIDDM patients. Diabetes care. 1993; 16(9):1296–7. Epub 1993/09/01. PMID: 8404436

20. Goda K, Sasaki E, Nagata K, Fukai M, Ohsawa N, Hahafusa T. Pancreatic volume in type 1 and type 2 diabetes mellitus. Acta diabetologica. 2001; 38(3):145–9. Epub 2001/02/02. https://doi.org/10.1007/s00125-001-0581-3 PMID: 11827436

21. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the
Evaluation of pancreas by imaging in diabetes

general population. American journal of physiology Endocrinology and metabolism. 2005; 288(2): E462–8. Epub 2004/09/02. https://doi.org/10.1152/ajpendo.00064.2004 PMID: 15339742

22. Rosqvist F, Iggman D, Kullberg J, Cederhaes J, Johansson HE, Larsson A, et al. Overfeeding polyunsaturated and saturated fat causes distinct effects on liver and visceral fat accumulation in humans. Diabetes. 2014; 63(7):2356–68. Epub 2014/02/20. https://doi.org/10.2337/db13-1622 PMID: 24550191

23. Kim SY, Kim H, Cho JY, Lim S, Cha K, Lee KH, et al. Quantitative assessment of pancreatic fat by using unenhanced CT: pathologic correlation and clinical implications. Radiology. 2014; 271(1):104–12. Epub 2014/01/31. https://doi.org/10.1148/radiol.13122883 PMID: 24475851

24. Tushuizen ME, Bunck MC, Pouwels PJ, Bonterms S, van Waesbergh JH, Schindhelm RK, et al. Pancreatic fat content and beta-cell function in men with and without type 2 diabetes. Diabetes care. 2007; 30(11):2916–21. Epub 2007/08/02. https://doi.org/10.2337/dc07-0326 PMID: 17666465

25. Heni M, Machann J, Staiger H, Schwenzer NF, Peter A, Schick F, et al. Pancreatic fat is negatively associated with insulin secretion in individuals with impaired fasting glucose and/or impaired glucose tolerance: a nuclear magnetic resonance study. Diabetes/metabolism research and reviews. 2010; 26(3):200–5. Epub 2010/03/13. https://doi.org/10.1002/dmrr.1073 PMID: 20225188

26. GA Wells BS, D O’Connell, J Peterson, V Welch, M Losos, P Tugwell. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis. 2016.

27. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. Journal of clinical epidemiology. 2008; 61(10):991–6. Epub 2008/06/10. https://doi.org/10.1016/j.jclinepi.2007.11.010 PMID: 18538991

28. Fonseca V, Berger LA, Beckett AG, Dandona P. Size of pancreas in diabetes mellitus: a study based on ultrasound. Br Med J (Clin Res Ed). 1985; 291(6504):1240–1. Epub 1985/11/02.

29. Yokota K, Fukushima M, Takahashi Y, Igaki N, Seino S. Insulin secretion and computed tomography values of the pancreas in the early stage of the development of diabetes. Journal of diabetes investigation. 2012; 3(4):371–6. Epub 2012/08/20. https://doi.org/10.1111/j.2040-1124.2012.00212.x PMID: 24843592

30. Kim MK, Chun HJ, Park JH, Yeo DM, Baek KH, Song KH, et al. The association between ectopic fat in the pancreas and subclinical atherosclerosis in type 2 diabetes. Diabetes research and clinical practice. 2014; 106(3):590–6. Epub 2014/12/03. https://doi.org/10.1016/j.diabres.2014.09.005 PMID: 25444353

31. Begovatz P, Koliaki C, Weber K, Strassburger K, Nowoty B, Nowotny P, et al. Pancreatic adipose tissue infiltration, parenchymal steatosis and beta cell function in humans. Diabetologia. 2015; 58(7):1646–55. Epub 2015/03/06. https://doi.org/10.1007/s00125-015-3544-5 PMID: 25740696

32. Basiratnia R, Hekmatia A, Kolahzir MR. Ultrasonographic alterations of pancreas in diabetic patients. Journal of Medical Sciences. 2012; 12(1):21–3.

33. Rajput R, Ram M, maheshwari S, Goyal RK, Verna GL. Pancreatic imaging by ultrasound in type 1 diabetes mellitus. Int J Diabetes & Metab. 2001; 9:75–80.

34. Williams AJ, Chau W, Callaway MP, Dayan CM. Magnetic resonance imaging: a reliable method for measuring pancreatic volume in Type 1 diabetes. Diabetic medicine: a journal of the British Diabetic Association. 2007; 24(1):35–40. Epub 2007/01/18.

35. Saisho Y, Butler AE, Meier JJ, Monchamp T, Allen-Aubach M, Rizza RA, et al. Pancreas volumes in humans from birth to age one hundred taking into account sex, obesity, and presence of type-2 diabetes. Clin Anat. 2007; 20(8):933–42. Epub 2007/09/20. https://doi.org/10.1002/ca.20543 PMID: 17879305

36. Sequeiros IM, Hester K, Callaway M, Williams A, Garland Z, Powell T, et al. MRI appearance of the pancreas in patients with cystic fibrosis: a comparison of pancreas volume in diabetic and non-diabetic patients. The British journal of radiology. 2010; 83(995):921–6. Epub 2010/10/23. https://doi.org/10.1259/bjr/24009651 PMID: 20965902

37. Williams AJ, Thrower SL, Sequeiros IM, Ward A, Bickerton AS, Triay JM, et al. Pancreatic volume is reduced in adult patients with recently diagnosed type 1 diabetes. The Journal of clinical endocrinology and metabolism. 2012; 97(11):E2109–13. Epub 2012/08/11. https://doi.org/10.1210/jc.2012-1815 PMID: 22879632

38. Burute N, Nisenbaum R, Jenkins DJ, Mirrahimi A, Anthwal S, Colak E, et al. Pancreas volume measurement in patients with Type 2 diabetes using magnetic resonance imaging-based planimetry. Pancreatology. 2014; 14(4):268–74. Epub 2014/07/27. https://doi.org/10.1016/j.pan.2014.04.031 PMID: 25062875

39. Gilbeau JP, Poncelet V, Libon E, Derue G, Heller FR. The density, contour, and thickness of the pancreas in diabetics: CT findings in 57 patients. AJR American journal of roentgenology. 1992; 159(3):527–31. Epub 1992/09/01. https://doi.org/10.2214/ajr.159.3.1503017 PMID: 1503017

40. Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol.
41. Ma J, Song Z, Yan F. Detection of hepatic and pancreatic fat infiltration in type II diabetes mellitus patients with IDEAL-Quant using 3.0T MR: comparison with single-voxel proton spectroscopy. Chinese medical journal. 2014; 127(20):3548–52. Epub 2014/10/16. PMID: 25316227

42. Kuhn JP, Berthold F, Mayerle J, Volzke H, Reeder SB, Rathmann W, et al. Pancreatic Steatosis Demonstrated at MR Imaging in the General Population: Clinical Relevance. Radiology. 2015; 276(1):129–36. Epub 2015/02/07. https://doi.org/10.1148/radiol.15140446 PMID: 26568030

43. Percival K, Macauley M, Steven S, Lim ES, Hollingsworth KG, Taylor R. Relationship between fat accumulation in liver and pancreas in type 2 diabetes and normoglycaemia. Diabetes Medicine. 2014; 31 (1):28–183.

44. Virostko J, Hilmes M, Eitel K, Moore DJ, Powers AC. Use of the Electronic Medical Record to Assess Pancreas Size in Type 1 Diabetes. PloS one. 2016; 11(7):e0158825. Epub 2016/07/09. https://doi.org/10.1371/journal.pone.0158825 PMID: 27391588

45. Regnell SE, Peterson P, Trinh L, Broberg P, Leander P. Pancreas volume and fat fraction in children with type 1 diabetes. Diabetic Medicine. 2016; 33(10):1374–79. https://doi.org/10.1111/dme.13115 PMID: 26996278

46. Geraghty EM, Boone JM, McGahan JP, Jain K. Normal organ volume assessment from abdominal CT. Abdominal imaging. 2004; 29(4):482–90. Epub 2004/03/17. https://doi.org/10.1007/s00261-003-0139-2 PMID: 15024516

47. Yun SP, Seo HI, Kim S, Kim DJ, Baek DH. Does the pancreatic volume reduction rate using serial computed tomographic volumetry predict new onset diabetes after pancreaticoduodenectomy? Medicine. 2017; 96(13):e6491. Epub 2017/03/30. https://doi.org/10.1097/MD.0000000000006491 PMID: 28353594

48. Bhargava R, Senior PA, Ackerman TE, Ryan EA, Paty BW, Lakey JR, et al. Prevalence of hepatic steatosis after islet transplantation and its relation to graft function. Diabetes. 2004; 53(5):1311–7. Epub 2004/04/28. PMID: 15111501

49. Maffi P, Angeli E, Bertuzzi F, Paties C, Socci C, Fedeli C, et al. Minimal focal steatosis of liver after islet transplantation in humans: a long-term study. Cell transplantation. 2005; 14(10):727–33. Epub 2006/02/04. PMID: 16454347

50. Leitao CB, Peixoto EM, Westphalen AC, Mireles-Zavala LG, Lauriola V, Bernetti K, et al. Liver fat accumulation after islet transplantation and graft survival. Cell transplantation. 2014; 23(10):1221–7. Epub 2013/06/28. https://doi.org/10.3727/096368913X668663 PMID: 23803321

51. Lee Y, Ravazzola M, Park BH, Bashmakov YK, Orci L, Unger RH. Metabolic mechanisms of failure of intraportally transplanted pancreatic beta-cells in rats: role of lipotoxicity and prevention by leptin. Diabetes. 2007; 56(9):2295–301. Epub 2007/06/15. https://doi.org/10.2337/db07-0460 PMID: 17563069